Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference32 articles.
1. International Diabetes Federation. IDF Diabetes Atlas 9th edn. (International Diabetes Federation, 2019).
2. Ali, M. K. et al. Achievement of goals in US diabetes care, 1999-2010. N. Engl. J. Med. 368, 1613–1624 (2013).
3. Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300–1304 (1987).
4. Nauck, M. A. et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273, E981–E988 (1997).
5. Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520 (1998).
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond;Metabolism;2024-02
2. Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial;Diabetes, Obesity and Metabolism;2023-12-15
3. Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?;Journal of Basic and Clinical Physiology and Pharmacology;2023-12-05
4. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials;Metabolism;2023-12
5. Neue Therapieziele in der Therapie des Diabetes mellitus Typ 2
– Gewichtsreduktion als co-primäres Therapieziel;Aktuelle Ernährungsmedizin;2023-12